COVID-19 Programs
Atossa has two programs to develop therapies to treat COVID-19: One called the COVID-19 HOPE Program which uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators and another called AT-301 Nasal Spray for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus.
Transforming the Breast Cancer Paradigm
-
Endoxifen
We are developing the promise of endoxifen and exploiting its potential to both help prevent as well as to treat breast cancer with our proprietary Topical and Oral Endoxifen.
-
Microcatheters
We are developing proprietary intraductal microcatheter technology for the potential delivery of drugs and immunotherapies (such as CAR-T) through the breast ducts directly to the site of the cancer.
Developing Solutions to Address all Sections of the Breast Cancer Paradigm
-
Prevention Window
-
Window-of-Opportunity (Pre-surgery)
-
Refractory (Post-surgery)
-
Gynecomastia
A Global Effort
We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner.
A Global Effort
We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner.
